Karyopharm Therapeutics (NASDAQ:KPTI) Given Buy Rating at HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $8.00 target price on the stock.

Karyopharm Therapeutics Stock Down 7.3 %

NASDAQ:KPTI opened at $1.02 on Thursday. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.79. The company has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $1.04. The company has a market cap of $118.80 million, a price-to-earnings ratio of -0.82 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $33.75 million during the quarter, compared to the consensus estimate of $33.50 million. During the same quarter last year, the business posted ($0.43) EPS. On average, analysts expect that Karyopharm Therapeutics will post -1.19 EPS for the current year.

Insider Buying and Selling

In related news, CFO Michael Mason sold 27,687 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $1.17, for a total value of $32,393.79. Following the completion of the sale, the chief financial officer now directly owns 404,918 shares of the company’s stock, valued at approximately $473,754.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO Michael Mason sold 27,687 shares of Karyopharm Therapeutics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $32,393.79. Following the transaction, the chief financial officer now directly owns 404,918 shares of the company’s stock, valued at approximately $473,754.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Richard A. Paulson sold 80,470 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $94,149.90. Following the sale, the chief executive officer now owns 1,183,783 shares of the company’s stock, valued at approximately $1,385,026.11. The disclosure for this sale can be found here. Insiders have sold 166,690 shares of company stock worth $197,094 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors have recently added to or reduced their stakes in KPTI. Bleakley Financial Group LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $33,000. Simplicity Solutions LLC acquired a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $33,000. Wade G W & Inc. acquired a new stake in shares of Karyopharm Therapeutics during the third quarter worth $60,000. SG Americas Securities LLC grew its position in Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock valued at $64,000 after buying an additional 54,839 shares during the last quarter. Finally, Simplicity Wealth LLC acquired a new position in Karyopharm Therapeutics in the 1st quarter valued at $66,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).